ESC Premium Access

Management of CV risk & type 2 diabetes mellitus (T2DM): implications of novel outcome trials.

Topic: Drug therapy
Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

Congress Presentation

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
52 presentations
3 followers

4 more presentations in this session

Introduction - Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure.

Speaker: Doctor D. Fitchett (Toronto, CA)

Thumbnail

SGLT2 inhibition in cardiology: what a cardiologist needs to know.

Speaker: Professor N. Sattar (Glasgow, GB)

Thumbnail

Heart failure & diabetes: time for a more unified approach.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Discussion - Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure.

Speaker: Doctor D. Fitchett (Toronto, CA) Professor J. Deanfield (London, GB)

Thumbnail

Access the full session

Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)

Speakers: Professor J. Deanfield, Doctor D. Fitchett, Professor N. Sattar, Professor S. Anker, Doctor D. Fitchett...
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb